Lista de obras -

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

scientific article published on 14 April 2020

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function

scientific article published on 08 April 2019

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis

artículo científico publicado en 2020

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

scientific article published on 22 November 2019

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

scholarly article by M Hasib Sidiqi et al published 8 November 2018 in Blood Cancer Journal

Comparative analysis of staging systems in AL amyloidosis

scientific article published on 23 January 2019

Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

artículo científico publicado en 2020

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

artículo científico publicado en 2020

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

artículo científico publicado en 2018

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

artículo científico publicado en 2018

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

scientific article published on 01 January 2019

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

artículo científico publicado en 2019

Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant

artículo científico publicado en 2020

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

artículo científico publicado en 2017

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells

artículo científico publicado en 2020

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis

scientific article published on 11 July 2019

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

scientific article published on 29 October 2019

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

scientific article published on 28 November 2019

Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias

scientific article published on 02 September 2014

Impact of acquired del(17p) in multiple myeloma

artículo científico publicado en 2019

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

artículo científico publicado en 2017

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis

artículo científico publicado en 2020

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma

scientific article published on 20 February 2019

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

artículo científico publicado en 2017

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity

scientific article published on 30 December 2019

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders

scientific article published on 30 May 2018

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

artículo científico publicado en 2015

Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy

artículo científico publicado en 2014

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis

artículo científico publicado en 2020

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

artículo científico publicado en 2017

Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis

artículo científico publicado en 2019

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

scientific article published on 26 September 2018

Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.

artículo científico publicado en 2014

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

artículo científico publicado en 2020

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma

scientific article published on 13 December 2018

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

scientific article published on 02 October 2018

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis

artículo científico publicado en 2019

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance

scientific article published on 30 January 2018

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy

artículo científico publicado en 2019

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method

scientific article published on 08 January 2019

Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio

artículo científico publicado en 2020

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

artículo científico publicado en 2018

Revisiting complete response in light chain amyloidosis

scientific article published on 26 November 2019

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

artículo científico publicado en 2018

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation

artículo científico publicado en 2018

Smoldering multiple myeloma requiring treatment: time for a new definition?

artículo científico publicado en 2013

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis

scientific article published on 23 September 2019

Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma

artículo científico publicado en 2013

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

scientific article published on 06 May 2020

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

artículo científico publicado en 2018

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2018

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

artículo científico publicado en 2019

Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia

artículo científico publicado en 2020

Venetoclax for the treatment of translocation (11;14) AL amyloidosis

scientific article published on 11 May 2020

Lista de obras de

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis

Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function

Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis

Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma

Comparative analysis of staging systems in AL amyloidosis

Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis

Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria

Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma

Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant

Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma

Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells

Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis

Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias

Impact of acquired del(17p) in multiple myeloma

Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).

Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis

Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma

Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis

Implications and outcomes of MRD-negative multiple myeloma patients with immunofixation positivity

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders

Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis

Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy

Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio

Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.

Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis

Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance

Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy

Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method

Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse

Revisiting complete response in light chain amyloidosis

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation

Smoldering multiple myeloma requiring treatment: time for a new definition?

Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis

Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia

Venetoclax for the treatment of translocation (11;14) AL amyloidosis